Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Carcinoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
Interventions: RADIATION: Copper Cu 64-DOTA-Trastuzumab|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pertuzumab|PROCEDURE: Positron Emission Tomography|PROCEDURE: Therapeutic Conventional Surgery|BIOLOGICAL: Trastuzumab
Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)